Acute decompensated heart failure

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

Retrieved on: 
Friday, September 30, 2022
Adult, Dialysis, Hospital, Congestion, AT, Trial of the century, COVID-19, Infection, Risk, SLOS, Company, Poster, Private Securities Litigation Reform Act, NDA, Heart failure, Patient, Length of stay, U.S. Securities and Exchange Commission, NIS, ADHF, Acute decompensated heart failure, Solution, Annual report, Diagnosis, Healthcare Cost and Utilization Project, NYHA, Security (finance), Pharmaceutical industry

If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

Key Points: 
  • If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
  • scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes.
  • The Companys lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Retrieved on: 
Tuesday, September 27, 2022
Heart, Hospital, Adult, Ultrafiltration, Cardiology, Nephrology, Trial of the century, Safety, Diuretic, USCF, COVID-19, Risk, University of California, San Francisco, Sodium, Division, Company, Growth, Private Securities Litigation Reform Act, Heart failure, Patient, University, Forward-looking statement, Disease, CEO, Quality of life, Acute decompensated heart failure, Nasdaq, Science, Randomized controlled trial, Clinical, Hypervolemia, Lenox Hill Hospital, GLOBE, SEC, Mortality, HF, Overload, UCSF, Pharmaceutical industry, Medicine, DRS, Medicine

Over 1 million heart failure hospitalizations occur annually in the United States, and fluid overload is the predominant cause in 90% of the patients.

Key Points: 
  • Over 1 million heart failure hospitalizations occur annually in the United States, and fluid overload is the predominant cause in 90% of the patients.
  • Fluid overload is a significant contributor to morbidity and mortality in heart failure patients.
  • REVERSE-HF is a multicenter, open-label, randomized controlled trial that is being conducted across the United States.
  • Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

Retrieved on: 
Tuesday, September 13, 2022
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Safety, Patient, Decompensation, U.S. Securities and Exchange Commission, University of Washington, The Valley Hospital, Physician, Nasdaq, Myocardial infarction, MPH, U.S. FDA, Survival, EDT, DO, Heart failure, Doctor of Philosophy, Heart, ABMD, PCI, Royal Brompton Hospital, FDA, Cardiomyopathy, News, ADHF, Cardiogenic shock, Security (finance), Conference, Northside Hospital, Blood volume, Faculty, Harefield Hospital, Program, Ascension Michigan, Mount Sinai Health System, Myocarditis, Quality of life, University of Pennsylvania Health System, Acute decompensated heart failure, Shock, Multimedia, University, STEMI, TCT, Tufts Medical Center, Medical device, Pharmaceutical industry, Abiomed, MD, Impella

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients.
  • Abiomeds booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist .
  • Future pipeline technology will be available to preview, including Impella ECP , Impella RP Flex, Impella BTR and preCARDIA .
  • Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD and Impella 5.5 with SmartAssist are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE

Retrieved on: 
Monday, July 18, 2022
SEC, I Corps (United States), CEO, Acute decompensated heart failure, Patient, Hospital, National Institute, NIH, Length of stay, Program, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Critical care, Software, Blood volume, COVID-19, Risk, U.S. Department of Defense Strategy for Operating in Cyberspace, Mortality, Â, CDSS, Heart failure, NHLBI, FDA, National Institutes of Health Clinical Center, Pharmaceutical industry

Oak Ridge, TN, July 18, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that it participated in the National Institute of Health (NIH) funded Innovation Corps (I-Corps™) program to accelerate commercialization of Daxor’s clinical decision support software (CDSS) to guide fluid management in acute decompensated heart failure.

Key Points: 
  • The I-Corps program is a highly-selective immersive, entrepreneurial training program open only to actively-funded NIH grant awardees.
  • The program prepares businesses to accelerate the economic and societal benefits of NIH-funded projects that are ready to move toward commercialization.
  • Participation in this program was funded by the NIH as a NIH Administrative Supplement to Daxors ongoing NHLBI SBIR grant and disbursed additional funds to the company as well to support its participation in the program.
  • Participating in the I-Corps program far exceeded our expectations and the learnings are extremely beneficial in accelerating the commercial rollout of our new software, said Shawn Urban, Daxor Senior Software Engineer.

The Worldwide Transcatheter Heart Valve Replacement Industry is Expected to Reach $11.8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 7, 2022
Health, Medical Devices, Cardiology, Prevalence, Percutaneous aortic valve replacement, Industry, Aortic valve, Government, TAVR, Medicare, Adrenal insufficiency, Stainless steel, Degenerative disease, Medicaid, Survival rate, Valvular heart disease, Heart, Cath lab, Risk, Hospital, Patient, Artery, American Heart Association, Cardiac arrest, Aortic stenosis, Acute decompensated heart failure, Transcatheter arterial chemoembolization, Physician, Infarction, Stroke, Insurance, Enlargement, Medical imaging

Over the past decade, transcatheter heart valve replacement has become the leading technique for aortic valve replacement, mitral valve replacement, and pulmonary valve replacement.

Key Points: 
  • Over the past decade, transcatheter heart valve replacement has become the leading technique for aortic valve replacement, mitral valve replacement, and pulmonary valve replacement.
  • Transcatheter heart valve replacement is a procedure with a less invasive approach that helps replace the heart valve with a prosthetic valve to treat severe aortic stenosis and mitral regurgitation.
  • Therefore, the growing cases of heart attacks, heart failures, strokes, and other heart-related conditions facilitate the market for transcatheter heart valve replacement.
  • On the basis of product, Transcatheter Heart Valve Replacement Market includes Transcatheter Aortic Vmeaningalve Replacement Market, Transcatheter Mitral Valve Replacement Market, and Transcatheter Pulmonary Valve Replacement Market.

WhiteSwell Adds Experienced Executives to its Senior Management Team

Retrieved on: 
Wednesday, January 26, 2022
Technology, Research, Medical Devices, Clinical Trials, Cardiology, Software, Hardware, Health, Science, Linda, University, Mechanical, Leadership, Canadian International Council, International Journal of Cardiology, Institute, Patient, Congestion, Mechanical engineering, Swelling, Nursing, Heart, VP, Engineer, HF, Clinical, Boston Scientific, National University of Ireland, Edema, Homeostasis, Integration, University of St. Thomas (Minnesota), National university, Diagnosis, Martin, Acute decompensated heart failure, Lymphatic system, Clinical trial, CEO, Tissue, Master of Engineering, Integrated assessment modelling, MBA, Hospital, Institution, Heart failure, Fatigue, Electronics, IDE, Pharmaceutical industry, Cardiology, ADHF, Medtronic, Science, the Lymphatic System and ADHF, WhiteSwell, THE LYMPHATIC SYSTEM AND ADHF, WHITESWELL

Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.

Key Points: 
  • Linda joins WhiteSwell from Medtronic, where she directed numerous clinical research teams.
  • She previously served as Vice President of Clinical Affairs at Respicardia, where she led successful execution of a randomized, pivotal IDE clinical trial.
  • Both Linda and Martin bring extensive experience and seasoned leadership to the WhiteSwell team, said Eamon Brady, CEO.
  • With a powerful senior management team in place, WhiteSwell is well positioned to advance its pioneering treatment of acute decompensated heart failure by leveraging the lymphatic system.

Cormeum App Celebrates Year of Helping Patients with Heart Failure Manage Condition

Retrieved on: 
Wednesday, January 12, 2022
Data Management, Health, Technology, Mobile, Wireless, Software, Cardiology, American Heart Association, Patient, Technology, Center, Acute decompensated heart failure, Health, Centers for Disease Control and Prevention, Innovation, Partnership, Google Play, Oxygen, Latin, Heart failure, Blood pressure, Muscle tissue, Caregiver, Self-management, Quality of life, American Heart, Multimedia, Blood, LLC, Human, Blog, Medical device

In January, Cormeum from the Latin cor meum or my heart began helping patients easily and intelligently track important metrics and relay that information to their providers through a convenient app.

Key Points: 
  • In January, Cormeum from the Latin cor meum or my heart began helping patients easily and intelligently track important metrics and relay that information to their providers through a convenient app.
  • The company now celebrates its first year of helping patients battle heart failure by tracking their lifestyle and condition and communicating in an all-new way with their care teams.
  • View the full release here: https://www.businesswire.com/news/home/20220112005230/en/
    This bridges the gap from patients to providers so they can work together to manage heart failure, said Lesley Hanselman, the apps creator.
  • Many people with heart failure lead full, enjoyable lives when their condition is managed well with heart failure medications and healthy lifestyle changes, according to the American Heart Association.

European Society of Cardiology Heart Failure Journal Publishes New Plasma Volume Heart Failure Study Data from FAST BioMedical

Retrieved on: 
Friday, December 10, 2021
Health, Science, Research, Clinical Trials, Cardiology, European Society of Cardiology, Biomedicine, Heart failure, Clinical trial, Hematocrit, Acute decompensated heart failure, Blood, Patient, Safety, Heart, FAST, Observational study, ESC, CHF, Association, Plasma, Technology, Pharmaceutical industry

FAST BioMedical (FAST) today announces the European Society of Cardiology (ESC) Heart Failure Journal has published additional results from its fourth human clinical trial.

Key Points: 
  • FAST BioMedical (FAST) today announces the European Society of Cardiology (ESC) Heart Failure Journal has published additional results from its fourth human clinical trial.
  • The published data indicate that estimated surrogate measurements for decongestion are not reflective of actual plasma volume status in hospitalized patients with acute heart failure.
  • Thirty-six heart failure patients were assessed for measured plasma volume, measured red cell volume and total blood volume using FAST Technology at two time points 48 hours apart during the course of diuretic therapy.
  • ESC Heart Failure is the open access journal of the Heart Failure Association that improves the understanding, prevention, investigation and treatment of heart failure.

First U.S. Patient Enrolled in Cardionomic's CPNS Pilot Study

Retrieved on: 
Tuesday, November 2, 2021
Safety, Weight gain, Acute decompensated heart failure, Hemodynamics, Pulmonary artery, Ohio State University Wexner Medical Center, ADHF, Patient, User experience, System, Federal, Disease, CEO, Ohio State University, Principal investigator, Committee, Breathe Me, Mortality, Hospital, Heart failure, Heart rate, Medical device, Pharmaceutical industry

The study is evaluating the safety and performance of the CPNS System in patients suffering from acute decompensated heart failure (ADHF), defined as new or worsening symptoms of heart failure.

Key Points: 
  • The study is evaluating the safety and performance of the CPNS System in patients suffering from acute decompensated heart failure (ADHF), defined as new or worsening symptoms of heart failure.
  • The first U.S. patient was enrolled and implanted at The Ohio State University Wexner Medical Center in Columbus, OH by Principal Investigator, Dr. Sitaramesh Emani, assisted by Dr. Rami Kahwash.
  • "The CPNS System provides a novel approach to improving cardiac contractility, rebalancing hemodynamics, and addressing both the root cause and symptoms of ADHF."
  • The CPNS System is an investigational device and is limited by Federal (or United States) Law to investigational use.

Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock

Retrieved on: 
Thursday, October 14, 2021
Director, Scientific programming language, European Society of Cardiology, Corporate Affairs, FDA, GLOBE, HK, University, Therapy, University of California, San Francisco, Research, WINT, Acute respiratory distress syndrome, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Alberta Students' Executive Council, Cardiogenic shock, American Heart Association, Patient, Q&A, Biotechnology, UCSF, KOL, Member, Association, Board, Hypertension, National Committee, Echocardiography, Heart Failure Society of America, American Association, ADHF, Hoffmann-La Roche, Heart failure, Nursing, COVID-19, Acute decompensated heart failure, Transplant, Respiratory distress syndrome, Faculty, Heart, Howard Hughes, Cardiology, Science, Medicine, Harvard Medical School, Executive Council, Pharmaceutical industry

Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.

Key Points: 
  • Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.
  • (UK) is Director of Heart Failure and of the Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California.
  • He also currently serves on the Acute Heart Failure Committee of the European Society of Cardiology Heart Failure Association and has served on the National Committee on Heart Failure and Transplantation of the American Heart Association.
  • Windtree Therapeutics, Inc.is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis.